Medicilon once again ranked on the 2024 Shanghai Hard Core Technology Enterprises TOP100 List

On March 22, the 2024 Shanghai Industrial Technology Innovation Conference was held with the theme of "Building the Main Engine of Innovation and Seizing New Opportunities in the Future". At this conference, Medicilon won the "2024 Shanghai Hard Core Technology Enterprises TOP100 List" with its hard-core technology and innovative technology service platform in the preclinical field of biopharmaceutical.

Medicilon once again ranked on the 2024 Shanghai Hard Core Technology Enterprises TOP100 List.webp

As a one-stop biopharmaceutical preclinical R&D service platform, Medicilon has always been committed to exploring hard-core technologies in the biopharmaceutical preclinical field. After 20 years of development, Medicilon now has 84,000 square meters of R&D laboratories and a high-quality R&D team. Through continuous technological innovation and R&D investment, we have conquered the core R&D technologies of new molecular types of drugs such as antibodies, peptides, ADCs, PROTACs, mRNA vaccines, small nucleic acid drugs, cell & gene therapy (CGT), and established a R&D service platform to empower and accelerate global pharmaceutical innovation. At the same time, Medicilon also has a wealth of innovative drug molecule design technology, relying on computer-aided drug design technology, high-throughput drug discovery technology, and bioelectronic isostere technology to establish a more efficient AI-guided drug design and synthesis platform to help clients improve R&D efficiency and reduce R&D barriers.

It is these hard-core scientific and technological innovation capabilities that have enabled Medicilon to empower 421 IND-approved clinical trials in the biopharmaceutical preclinical field, winning widespread recognition and praise, and attracting the favor of many partners. Looking forward to the future, Medicilon will continue to stride forward on the journey of technological innovation and industrial development, injecting continuous innovative vitality and power into the global biopharmaceutical industry!

此博客中的热门博文

In Vitro Enzyme Activity Assay

Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+ in vitro enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...

阅读全文

Fluorescence Probes Synthesis

Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. Design and synthesis steps Fluorescent probes are tools used to detect, measure and analyze biomolecules, cells and tissues. They achieve these purposes by emitting and receiving fluorescent signals. Medicilon can complete the design and synthesis of fluorescent probes for biomolecules. Selection of target molecules and determination of target. Selection of fluorescent dyes. Design of molecular structure. Synthesize probe molecules. Testing the properties of probe molecules. Custom synthesis Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. After years of development, Medicilon's fluorescent probes and labeling platforms have accumulated rich experience...

阅读全文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services

阅读全文

Shanghai Medicilon Inc.

搜索此博客